Boston Scientific Reports FDA Approval for Heart Failure Devices; Teva Unveils Generic Lunesta Tablets in US Print E-mail
By Staff and Wire Reports   
Tuesday, 15 April 2014 18:49
Below is a look at some of the headlines for companies that made news in the healthcare sector on April 15, 2014.
Boston Scientific Corporation (NYSE: BSX) has received FDA approval for its latest generation of defibrillators and heart failure devices designed to advance patient care. The newly approved devices include the DYNAGEN™ MINI and INOGEN™ MINI ICDs, as well as the DYNAGEN™ X4 and INOGEN™ X4 CRT-Ds.

The X4 line of quadripolar CRT-Ds offers 70 percent more pacing options to address high capture thresholds and phrenic nerve stimulation effectively, along with the largest battery capacity in the industry. These newly approved devices continue the Boston Scientific history of industry-leading projected longevity and a six-year CRT-D warranty.

Extending the Boston Scientific portfolio of defibrillators, the ICDs in the MINI family are the world's smallest and thinnest devices and are designed for patient comfort. The small dimensions of the MINI ICD are up to 20 percent smaller by volume and up to 24 percent thinner than competitive devices from other manufacturers.[i]

"The tiny size of the MINI ICD provides a real benefit to some patients, in particular those with a smaller frame," said Prof. Dr. Hans-Joachim Trappe from University Marien Hospital Herne, Hospital of Ruhr-University, Bochum, Germany. "The MINI ICD not only improves patient comfort, but also provides these patients with innovative technology to help treat life-threatening arrhythmias of the heart."

"With these new devices and our current line of long-lasting ICDs and CRT-Ds, including the world's only subcutaneous ICD, we believe we offer the very best range of options for patients at risk of sudden cardiac arrest with or without the need for cardiac resynchronization therapy," said Joe Fitzgerald, executive vice president and president for the Rhythm Management division of Boston Scientific. "Our devices simply offer more options to improve outcomes, reduce complications and lower the costs of treating patients."


=====================


Teva Pharmaceutical Industries Ltd. (NYSE: TEVA)
announces the launch of the generic equivalent to Lunesta® (Eszopiclone Tablets, CIV), 1, 2 and 3 mg, in the United States.

Lunesta® Tablets, marketed by Sunovion Pharmaceuticals, had annual sales of approximately $852 million in the United States, according to IMS data as of December 2013.



Also Tuesday:



Abiomed, Inc. (Nasdaq:ABMD)
, a leading provider of break-through heart support technologies, today announced its acquisition of an exclusive license from collaboration partner Opsens (TSX-V:OPS), a leading developer of fiber optic sensors.

Alliqua, Inc. (Nasdaq:ALQA), a provider of advanced wound care products, has raised $20.3 million in a series of transactions that included a $15.0 million private placement of common stock and warrants and $5.3 million from the exercise of warrants from several institutional shareholders.

In a release issued earlier today under the same headline by Alliqua, Inc. (Nasdaq:ALQA), please note that details of the common stock price of $7.00 per share have been added to paragraph two. 

Eternity Healthcare Inc. (OTC:ETAH)
, a leading medical device and diagnostic company with special focus on diabetes management, announced today that it has signed a Letter of Intent (LOI) to license technologies from Kinexus Theranostics.

Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX),
a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of renal disease, today announced the appointment of three key executives in high priority strategic roles integral to the preparation for the potential Zerenex™ (ferric citrate coordination complex) product launch.

LifeVantage Corporation (Nasdaq:LFVN)
, a company dedicated to helping people achieve healthy living through a combination of a compelling business opportunity and scientifically validated products, today announced that it has acquired a line of sports nutrition products known as Wicked Fast Sports Nutrition.

Hemp, Inc. (OTC:HEMP)
announced today that Greene Concepts, Inc. (OTC:LKEN), one of its 'Community of Companies', has officially launched The Hemp Exchange (http://hemp-x.com) after weeks of beta testing.

Nuvilex, Inc. (OTCQB:NVLX)
, a clinical-stage international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that it has contracted Clinical Network Services Pty Ltd (CNS), a fully integrated drug development company based in Australia, New Zealand and the United Kingdom, to handle every aspect of Nuvilex's late-phase clinical trials in pancreatic cancer as Nuvilex's Contract Research Organization (CRO).

Sharps Compliance Corp. (Nasdaq:SMED)
announced that Diana Diaz, Chief Financial Officer, will be presenting at the 18th Annual Burkenroad Reports Investor Conference, organized by the Freeman School of Business at Tulane University.




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter